Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...

Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...

Em­bat­tled ge­net­ics test­ing gi­ant 23andMe is think­ing of sell­ing it­self as it runs out of cash. The com­pa­ny needs ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year ...

Few companies had a year as bumpy as 23andMe had in 2024, with the company settling a lawsuit related to a data breach and announcing a round of layoffs. Amid that turmoil, many of the popular ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

in order to update my prior statement and avoid any confusion in the market, I am no longer open to considering third-party takeover proposals for the Issuer," she said in the filing. A 23andMe ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

My 23andMe process was simple; I showed up to a Quest Diagnostics, where a phlebotomist drew several vials of blood, like a normal test. Weeks (and weeks) passed, but all my results eventually ...

Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...